http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112553323-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0003 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 |
| filingDate | 2020-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112553323-B |
| titleOfInvention | COL1A1 as a biomarker of type 2 diabetes and its application |
| abstract | The present invention relates to the application of a novel Col1a1 protein as a biomarker for identifying type 2 diabetes. It is found in the experiments of the present invention that the expression of Col1a1 protein in the jejunum of the type 2 diabetic rat group is significantly smaller than that in the jejunum of the oligosaccharide prolifera and the normal rat group. Liquid mass spectrometry-based tandem mass tagging (TMT) indicated Col1a1 as the most influential protein receptor in the ECM pathway. In the present invention, the changes of Col1a1 protein in transcription and protein level are further examined by fluorescence quantification and western blot, which proves that Col1a1 protein will be a new therapeutic target and biomarker for type 2 diabetes. |
| priorityDate | 2020-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 764.